HDAC6 and cancer: Our data demonstrated that the intracellular concentration of citarinostat and the HDAC6 inhibiting activity were significantly reduced by ABCB1 and ABCG2, and consequently, cancer cells overexpressing ABCB1 or ABCG2 are insensitive to citarinostat.